These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6344976)

  • 1. 5-Fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM): an effective program for breast cancer, even for disease refractory to previous chemotherapy. A Northern California Oncology Group (NCOG) Study.
    Friedman MA; Marcus FS; Cassidy MJ; Resser KJ; Kohler M; Hendrickson CG; Reynolds R; Johnson D; Kilbridge T; Yu K; Cruicitt M
    Cancer; 1983 Jul; 52(2):193-7. PubMed ID: 6344976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report.
    Oster MW; Park Y
    Cancer; 1983 Jan; 51(2):203-5. PubMed ID: 6821812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
    Shipp SK; Muss HB; Westrick MA; Cooper MR; Jackson DV; Richards FC; White DR; Stuart JJ; Christian RM; Ramseur W
    Cancer Chemother Pharmacol; 1983; 11(2):130-3. PubMed ID: 6354509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma.
    Luikart SD; Witman GB; Portlock CS
    Cancer; 1984 Oct; 54(7):1252-5. PubMed ID: 6467151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Fluorouracil and mitomycin C in advanced breast cancer.
    Aspegren K; Landberg T
    Radiother Oncol; 1986 Jun; 6(2):121-6. PubMed ID: 3090650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study.
    Haas CD; Mansfield CM; Leichman LP; Considine B; Bukowski RM
    Cancer Treat Rep; 1983 May; 67(5):421-4. PubMed ID: 6687837
    [No Abstract]   [Full Text] [Related]  

  • 7. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).
    Douglass HO; Lavin PT; Goudsmit A; Klaassen DJ; Paul AR
    J Clin Oncol; 1984 Dec; 2(12):1372-81. PubMed ID: 6439836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
    Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
    DiStefano A; Yap HY; Blumenschein GR
    Cancer Treat Rep; 1981; 65(1-2):33-8. PubMed ID: 7013977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide, methotrexate,5-fluorouracil, alternating with adriamycin and mitomycin C in metastatic breast cancer: a pilot study.
    Cruciani G; Tienghi A; Molinari AL; Fiorentini G; Rosti G; Turci D; Marangolo M
    Tumori; 1987 Jun; 73(3):303-7. PubMed ID: 3111046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adriamycin, vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma.
    Harding M; Sangster G; Milsted RA; Kaye SB; Calman KC
    Med Oncol Tumor Pharmacother; 1988; 5(2):125-8. PubMed ID: 3412036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility study of combining metronidazole with chemotherapy.
    Stewart DJ; Maroun JA; Young V; Crook AF; Hopkins HS; Yan RC; Richard MT; Hugenholtz H; Bélanger R; Heringer R
    J Clin Oncol; 1983 Jan; 1(1):17-23. PubMed ID: 6422002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients.
    Ardizzoni A; Pronzato P; Conte PF; Rosso R
    Chemioterapia; 1984 Apr; 3(2):83-5. PubMed ID: 6442624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Colozza M; Tonato M; Grignani F; Davis S
    Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].
    Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Tada A; Ueno K; Yamazaki H; Nakamura T; Ito Y; Inagaki J
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):327-32. PubMed ID: 2494947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer.
    Falkson G; Gelman RS; Tormey DC; Taylor SG; Falkson HC
    Cancer Treat Rep; 1985; 69(7-8):755-60. PubMed ID: 4016786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
    Tormey DC; Gelman R; Band PR; Sears M; Rosenthal SN; DeWys W; Perlia C; Rice MA
    Cancer; 1982 Oct; 50(7):1235-44. PubMed ID: 7049347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy.
    De Lena M; Jirillo A; Brambilla C; Villa S
    Tumori; 1980 Aug; 66(4):481-87. PubMed ID: 7414712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM).
    Paul AR; Engstrom PF; Weiner LM; Steplewski Z; Koprowski H
    Hybridoma; 1986 Jul; 5 Suppl 1():S171-4. PubMed ID: 3527946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.